Type 1 plasminogen activator inhibitor (PAI-1) and its cofactor vitronectin (Vn) are stored within the a-granules of platelets. The two possible sources for their biosynthetic origin are endogenous synthesis in megakaryocytes or endocytosis from plasma. Using ultrastructural and confocal laser scanning microscopic (CLSM) image analysis, we observed that treatment of Dami cells, a human megakaryocytic cell line, with phorbol myristate acetate (PMA) induces the accumulation of PAL1 and Vn in intracellular storage vacuoles that contain other a-granule proteins such as von Willebrand factor. To examine evidence for biosynthesis of PAL1 and Vn by Dami cells, we immunoprecipitated PAL1 and Vn from the conditioned media of cells biosynthetically radiolabeled with '%-methionine in the presence or absence of PMA. In contrast t o Hep G2 cells, which synthesize both PAL1 and Vn, only '5S-PAI-1 was recovered from PMA-treated Dami cells. Reverse transcription-PCR analysis of RNA extracted from resting and PMA-treated Dami cells confirmed that PAI-1 mRNA expression was detectable at low levels in resting LATELETS MAY influence thrombolysis due to the presence of type 1 plasminogen activator inhibitor (PAI-1) and vitronectin (Vn) in their a-granules.' PAI-1 is the major physiologic regulator of fibrinolysis. It binds to and inactivates tissue-and urokinase-type plasminogen activator and thus inhibits the generation of plasmin. PAI-1 circulates bound to Vn and is stabilized by this interaction.'.' Moreover, recent studies indicate that platelet-associated PAI-1 is largely responsible for inhibiting the lysis of platelet-rich thrombi.6"' There is also evidence that PAL1 is released from activated platelets in association with Vn.' Thus, Vn associated with platelet a-granules may be an important mechanism for modulating platelet-associated PAI-1 activity.
Type 1 plasminogen activator inhibitor (PAI-1) and its cofactor vitronectin (Vn) are stored within the a-granules of platelets. The two possible sources for their biosynthetic origin are endogenous synthesis in megakaryocytes or endocytosis from plasma. Using ultrastructural and confocal laser scanning microscopic (CLSM) image analysis, we observed that treatment of Dami cells, a human megakaryocytic cell line, with phorbol myristate acetate (PMA) induces the accumulation of PAL1 and Vn in intracellular storage vacuoles that contain other a-granule proteins such as von Willebrand factor. To examine evidence for biosynthesis of PAL1 and Vn by Dami cells, we immunoprecipitated PAL1 and Vn from the conditioned media of cells biosynthetically radiolabeled with '%-methionine in the presence or absence of PMA. In contrast t o Hep G2 cells, which synthesize both PAL1 and Vn, only '5S-PAI-1 was recovered from PMA-treated Dami cells. Reverse transcription-PCR analysis of RNA extracted from resting and PMA-treated Dami cells confirmed that PAI-1 mRNA expression was detectable at low levels in resting LATELETS MAY influence thrombolysis due to the presence of type 1 plasminogen activator inhibitor (PAI-1) and vitronectin (Vn) in their a-granules.' PAI-1 is the major physiologic regulator of fibrinolysis. It binds to and inactivates tissue-and urokinase-type plasminogen activator and thus inhibits the generation of plasmin. PAI-1 circulates bound to Vn and is stabilized by this interaction.'.' Moreover, recent studies indicate that platelet-associated PAI-1 is largely responsible for inhibiting the lysis of platelet-rich thrombi.6"' There is also evidence that PAL1 is released from activated platelets in association with Vn.' Thus, Vn associated with platelet a-granules may be an important mechanism for modulating platelet-associated PAI-1 activity.
Although there is evidence that PAI-1 is synthesized by megakaryocytes and megakaryocyte-type cell lines,l3.l4 the biosynthetic origin of Vn in a-granules is unknown. Three possible mechanisms exist for the targeting of proteins to the platelet a-granule, including (1) endogenous synthesis within the precursor megakaryocyte, (2) receptor-dependent endocytosis, or (3) receptor-independent uptake by platelets or megakaryocytes." The purpose of this study was to examine the biosynthetic origin of PAI-I and Vn in Dami cells, a permanent line of cultured megakaryocytes isolated from a human megakaryoblastic leukemia.I6 These cells can be induced to differentiate down the megakaryocytic lineage by treatment with the tumor promoter phorbol-myristate-acetate (PMA) and thus can be used to examine the biochemical events of megakaryocyte differentiation.
In this report, we present evidence consistent with the hypothesis that platelet Vn arises from transport into the agranule from the surrounding medium, whereas PAI-l is synthesized by the precursor megakaryocyte and deposited in the a-granule before the platelet is shed. ticware, RPMI medium, a-minimal essential medium (a-MEM), methionine-free RPMI, calf and goat serum, Hank's Buffered Salt Solution (HBSS), trypsin, penicillin, streptomycin, streptavidin-conjugated Texas Red, and goat antimouse IgG-conjugated fluorescein isothiocyanate (FITC) were obtained from GIBCO BRLLife Technologies Inc (Burlington, Ontario, Canada). Bovine skin gelatin, PMA, leupeptin, soybean trypsin inhibitor, phenylmethylsulfonyl fluoride, N-ethyl maleimide, benzamidine, aprotinin, casein, Triton X-100, caprylic acid, normal goat IgG, normal rabbit IgG, and isotype-matched, nonspecific mouse IgG were obtained from Sigma Chemical CO (St Louis MO). The monoclonal antibody (MoAb) MAI-12 IgG was obtained from Biopool (Burlington, Ontario, Canada). Purified IgG fractions of monoclonal and polyclonal antibodies were prepared by caprylic acid precipitation." Antisera to human PAL1 or human Vn were raised in rabbits, and the IgG fractions further purified by affinity chromatography on immobilized PAI-I or Vn, respectively." The polyclonal antibodies to PAI-I and Vn were shown to be monospecific by immunoblot analysis of human Isolation of Vn from human plusma. Vn was isolated from human plasma by one of two methods, including (1) denaturing urea and heparin-Sepharose affinity chromatography22 and (2) nondenaturing heparin Sepharose and immunoaffinity chromatography. For immunoaffinity chromatography, human plasma (50 mL) was equilibrated with 20 mmol/L Tris, 0.15 m o m NaCI, pH 7.4, and passed over a 15-mL heparin Sepharose precolumn tandemly coupled to an affinity-purified sheep anti-Vn IgG Affi-gel affinity column. Vn was eluted under nondenaturing conditions using Gentle Antibody Elution buffer (Pierce Biochemical, Rockford, IL). Native Vn was homogeneous for the 75-kD, single-chain and a two-chain form.
P

MATERIALS AND METHODS
Chemicals
To prepare multimeric Vn, native Vn preparations were treated with 6 mol/L urea for 1 hour followed by extensive dialysis." Vn was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)24 and native-PAGE and quantitated using both Micro BCA protein assays (Pierce Chemical) and Vn-specific competitive ELISAs using polyclonal and conformation-sensitive MoAbs to human Vn. MoAb 8E6 was obtained from Boehringer Mannheim (Montreal, Quebec, Canada). MoAbs 153 and 1244 were kindly provided by Dr D. Seiffert.*'
Biotinylation of puri$ed proteins. Purified proteins (PAI-1 and Vn) were biotinylated with biotinyl-t-amino caproic-N-hydroxysuccinimide ester (Boehringer Mannheim) following the manufacturer's instructions. Briefly, 100 pg of protein in phosphate-buffered saline (PBS) was adjusted to pH 7.7 with bicarbonate buffer and then incubated with 10 pg biotinylation reagent in dimethylformamide (25 mg/mLj for 2 hours at room temperature. Labeling mixtures were dialyzed against several volumes of PBS, pH 7.4. and aliquots were stored at -70°C until used. The bioactivity of biotinylated PAI-I (b-PAI-I) was determined by measuring its ability to bind to Vn or tissue-type plasminogen activator (t-PA)-coated 96-well plates.Ix Bound b-PAI-l was detected directly with streptavidinconjugated alkaline phosphatase or indirectly with rabbit anti-PAI-I and goat antirabbit IgG-conjugated alkaline phosphatase followed by pNPP substrate, and the rate of change in the absorbance at 405 nm was quantitated using a microtiter plate reader (EL 340; Bio-tek Instruments Inc. Highland Park, VT). Biotinylation of PAI-I did not block PA[-I binding to t-PAor PAI-l-mediated inhibition of t-PA activity, as assessed using the chromogenic substrate S-2251 (Chromogenix; Helana Laboratories, Mississauga, Ontario, Canada). Biotinylation had no effect on the binding of PAI- Vn incorporation into Dumi cells. Cells (2.5 X 10' in 50 pL) were harvested as described above and incubated for various lengths of time at either4"C or 37°C with 4 pg/mL h-Vn and then centrifuged to separate the bound from the free b-Vn. The pellets were resuspended in 500 pg/mL trypsin for 2 minutes at room temperature to digest any surface-associated b-Vn and the trypsin inactivated by the addition of 750 FL of ice-cold HBSS containing 20% FBS. Flow cytometry analysis, as described above, confirmed that this treatment removed greater than 95% of the b-Vn from cells incubated in the presence of the ligand at 4°C. The cells were again pelleted, the supernatant was removed, and the cell pellet was frozen at -70°C until analyzed. The pellets were thawed in 1 X Laemmli sample buffer containing P-mercaptoethanol and fractionated by SDS-PAGE" under reducing conditions and the proteins were electroblotted onto nitroceliulose paper. The filters were blocked with PBS containing 5% fat-free milk and 0.5% Triton X-100, probed with 0.25 pCi/mL "'I-streptavidin, washed, and exposed to x-ray film at -70°C. The resulting autoradiographic bands at 65 kD were examined using a scanning laser densitometer. Band density is expressed as absorbance units times millimeter. To assess specific uptake, the density of the band from cells incubated at 4°C was subtracted from that of the cells incubated at 37°C. For some studies, cells were viewed by video enhanced fluorescence microscopy using an epifluorescence microscope (Leica Laborlux S; Willowdale, Ontario, Canada) fitted with a 63X planapo oil immersion lens (na = 1.4), a 100 W mercury lamp, and transmission filters for FITC (525 nm) and TxR (600 nm long pass filter). Images were captured using a CCD video camera module electronically linked to a computer imaging software system (Northern Exposure; Empix Inc, Mississauga, Ontario, Canada).
To discriminate the relative spatial distribution of intracellular and extracellular PAL1 and Vn, cultured Dami cells were analyzed by dual-labeling immunofluorescence confocal laser scanning microscopy (CLSM) and subjected to 2-plane optical sectioning (200 nm/ section). Optical sectioning of cells was performed using a Zeiss LSM 10 equipped with a 63X planapo oil immersion lens (numerical aperture, 1.4). Dual-wavelength images were acquired using an argon ion laser (488 nm excitation), a helium/neon ion laser (543 nm excitation), and two matched long pass barrier filters for FITC (515 to 525 nm emission) and TxR (575 to 640 nm emission) images. Image processing and three-dimensional volume rendering and rotations were performed on Metamorph software (Empix Imaging Inc). Before analysis, all images were Z-plane line averaged and corrected for dark current and instrument background. Cells stained with nonspecific primary antibodies or streptavidin-FITC alone were used to establish background intensity.
To examine the uptake and intracellular location of b-Vn, cells were grown on coverslips and were exposed to 4 pg/mL b-Vn for 6 hours at 37"C, washed, and not only immunologically stained for PAI-1 as above, but also probed for internalized b-Vn with streptavidin-FITC, and then analyzed by dual-labeling immunofluorescence confocal microscopy and 2-plane optical sectioning as described above.
For postembedding immunogold electron microscopy, resting or PMA-treated (24 hours) Dami cells were processed in LR White medium without postfixation by osmium tetr~xide.'~ Thin sections were mounted on Formvar-coated, nickel-plated grides and incubated overnight with affinity-purified rabbit anti-PAI-l, anti-Vn, or preimmune rabbit IgG. The sections were washed with PBS and incubated with gold-conjugated (10 nm) goat antirabbit IgG. All sections were double-stained with uranyl acetate and lead citrate. Specimens were examined with a Joel Biosystems (Montreal, Quebec, Canada) 1200 electron microscope at 75 kV.
Metabolic labeling and immunoprecipitation. Dami cells (confluent @-mm dishes) were metabolically labeled for 24 hours with 100 pCi/mL 35S methionine (NENmuPont Canada, Mississauga, Ontario, Canada) in 3 mL of 90% methionine-reduced medium (4 mmolk), as previously des~ribed.~",~' To show the secretion of radiolabeled PAI-I or Vn, conditioned media were centrifuged to remove cell debris, precleared with protein A-Sepharose, and then incubated with affinity-purified rabbit anti-PAI-l or anti-Vn IgG bound to protein A-Sepharose beads in immunoprecipitation buffer containing 0.1 mmoliL iodoacetamide, 0.2 mmolfL phenylmethyl sulfonyl fluoride (PMSF), and 5 nmol/L N-ethyl maleimide.** The beads were washed to remove unbound proteins and the bound proteins were subjected to SDS-PAGE.Z4 The gels were dried and exposed to x-ray film (Kodak XR; Eastman Kodak, Rochester, NY) for autoradiography at -70°C.
RT-PCR and Southern blot analysis. Total RNA was isolated from either control or PMA-treated Dami cells and human hepatoma Hep G2 cells using the method of Chomzynski and Sacchi." Oligonucleotide primers were as follows. The PAI-I forward 5"CGGAG-CACGGTCAAGCAAGTG-3' and PAL 1 reverse S-GGTGAGGG-CAGAGAGAGGCAC-3' primers were used to amplify a 400-bp fragment near the 3' end of the PAI-l cDNA. Vn forward 5'-GAGC-GGGACAGCTGGGAGGAC-3' and reverse 5"AGGAGCTGGG-CAGCCCAGCC-3' primers were used to amplify a 501-bp fragment also in the 3' end of the Vn cDNA. Primers for glyceraldehyde-3-phosphate dehydrogenase (GAPDH; forward, 5'-CCCATGGCA-AA'ITCCATGGCA-3'; reverse, 5"TCTAGACGGCAGGTCAGG-TCGACC-3') amplify a 600-bp fragment. 33 The reverse transcription reaction to synthesize cDNA was performed using 1 pg of total RNA, branes were then wrapped in plastic wrap and exposed to Kodak Xmat AP film at -70°C for I to 3 days.
RESULTS
Immunostaining of PAI-I and Vn. We have previously shown that PMA-induced differentiation of Dami cells results in the de novo synthesis and colocalization of vWF and multimerin within the extensive network of precursor platelet a-granule-like storage vacuoles.30 To determine whether PMA also influences the expression of PAL1 and Vn within the vWF-positive storage granules, we performed dual-labeling immunofluorescence CLSM image analysis on fixed, permeabilized Dami cells that were preincubated for 24 hours in the presence or absence of PMA (Fig 1) . Dami cells were cultured on coverslips and incubated in the final 24 hours in the presence or absence of PMA. The cells were fixed, permeabilized and stained for PAX-l, Vn, and vWF (Fig l) . Untreated cells did not adhere to the coverslips and were therefore prepared by cytocentrifugation before fixation and staining (see Fig 3D) . Figure 1A illustrates the differential contrast of adherent, PMA-treated Dami cells that were stained for Vn (Fig 1B) and PAI-1 (Fig 1C) . These pseudocolored images represent the composite of varying fluorescence from all optical planes and show that the greatest intensity of stain (red > yellow > green > blue) for both antigens is located in the large vacuolar structures that radiate (Fig 1D) indicates only a faint background fluorescence. Single-plane images of PMAtreated cells dual-labeled for vWF (Fig 1E) and PAI-1 ( Fig  1F) show distinct, yet clearly overlapping images (arrows) for the areas of most intense staining, thus identifying these structures as a-granule-like vacuoles. Figure 1G and H illustrate the higher magnification of a pseudocolor image through the perinuclear region from two PMA-treated cells stained for Vn (Fig 1G) and PAI-1 (Fig 1H) . Distinct yet overlapping distributions of these two proteins can be seen in the large storage granules. Ninety degree rotation of the Z-plane cross-sections of the entire stack of optical sections taken through the vertical line in Fig 1G and H are presented in G' and H', respectively. Again, distinct, yet overlapping distributions of Vn and PAI-1 can be seen (small arrows).
Cells stained with preimmune IgG were similar to non-PMA-treated cells stained for PM-1 (Fig ID, data not  shown) . Staining for Vn in non-PMA-treated cells was localized in similar structures and equally as intense as that for PMA-treated cells.
To further examine the subcellular location of PAI-1 and
Vn, Dami cells were treated in the presence or absence of PMA for 24 hours, the cells were harvested and pelleted, and the cell pellets prepared for postembedding immunogold electron microscopy. Figure 2A shows a low-power view of a PMA-treated D& cell stained for PAI-1 and shows the extensive network of convoluted vacuoles in Dami cells, as seen in Fig 1. The PAI-1 immunogold labeling in these vacuoles (arrow) is localized to characteristic branching filamentous matrix structures. These can be seen in high magnification in Fig 2D. As in Fig lD, PAI-l labeling is not detected in untreated, control cells (Fig 2C) . Vn is also present among the fibrillar matrix and was also among the amorphous proteinaceous aggregates localized within these storage granules in both untreated (Fig 2E, arrows) and PMA-treated cells (Fig 2F, arrows) . PMA treatment of the cells had no apparent effect on the pattern of the Vn staining. Staining of PMA-treated Dami cells with preimmune rabbit IgG did not show labeling in these vacuoles (Fig 2B) .
Immunoprecipitation of biosynthetically radiolabeled proteins. To examine the metabolic origin of PAI-1 and Vn, we next examined the evidence for endogenous synthesis of these molecules. Dami cells, in the presence or absence of 5 nmol/L PMA, were incubated for 24 hours in the presence of 35S-methionine and methionine-reduced medium. The culture supernatant was collected and immunoprecipitated with either normal rabbit IgG, affinity-purified rabbit antihuman PAI-1, or antihuman Vn IgG. Precipitated radiolabeled proteins were separated by SDS-PAGE and visualized by autoradiography (Fig 3) . Even after prolonged exposure, radiolabeled Vn was not detected in the conditioned medium from the basal or PMA-treated cells (lanes 2 and 5) . The results from immunoprecipitation analysis of the Triton X-100 soh- ble cell lysates and Triton X-l00 insoluble extracellular matrix extracts showed no evidence of "S-labeled Vn in these cell compartments (data not shown). 
RT-PCR analysis.
A second approach was used to examine the evidence for endogenous synthesis of PAI-I and Vn at the RNA level. Total RNA was isolated from cells that were incubated in the presence or absence of PMA for 24 hours, and the RNA was subjected to reverse transcription and PCR amplification using primers specific for PAI-I and Vn. Vn mRNA was not present in either control or PMAtreated Dami cell extracts, but was present in the Hep G2 cell extracts (Fig 4A, lanes 6, 7, and 8) . However, PAI-I transcripts were present in untreated cell extracts. Treatment of the cells with PMA for 24 hours before harvest resulted in an increase in PAI-I transcripts, as evidenced by an increase in the band intensity of the amplicon (Fig 4A, lanes  2 and 3) . Equal loading of RNA was confirmed by the equal signal of all three cell extracts for GAPDH (Fig 4A, lanes  IO. 11, and 12 ). Southern blot analysis using radiolabeled PAI-I and Vn cDNA probes confirmed the identity of the amplicons (Fig 4B) .
Ligand binding and uptake studies. Because endogenous expressions and synthesis of Vn could not be shown, we examined the evidence for an exogenous origin of Vn (and PAI-I) from plasma. Dami cell suspensions were incubated for 1 hour at 4°C in the presence of various concentrations of native or multimeric b-Vn followed by RTC-conjugated streptavidin and then subjected to flow cytometry analysis. As shown in Fig 5, Table 1 illustrates the effects of various agents on the binding of bVn to Dami cells. Binding was inhibited approximately 90% by the addition of 10% FBS. RGE-or RGD-containing peptides (up to 1,000-fold excess) had no effect on the b-Vn to remove cell surface-associated b-Vn. the cell lysates were in a time-dependent internalization, as shown by the increase 13) were reverse-transcribed and PCR-amplified using primers for a 401-bpfragment of PAL1 cDNA llanes2through 5). a 501-bpfragment in the 65-and 75-kD Vn bands (Fig 6A) . Cells incubated at of vn c~~~ (lanes 6 through g), or a 6 0 0 -b~ fragment of GAPDH 4°C incorporated significantly less b-Vn. To better illustrate cDNA (lanes 10 through 13). Molecular weight markers are in lanes 1 (123-bp ladder) and 14 (100-bp ladder). (B1 To confirm the identity of the amplicons produced using the PAL1 and Vn primers, RT-PCR products from lanes 2, 3, and 4 (PAI-1 primers) and lanes 6, 7, and 8 (Vn primers) were transferred t o nitrocellulose paper and probed with radiolabeled cDNA for PAI-1 (left) and Vn (right), respectively. For the specific time-dependent uptake of b-Vn. the autoradiograph bands of the 65-kD Vn were quantitated at each time point by laser densiometry and the intensity of the corresponding band at 4°C was then subtracted from that at 37°C (Fig 6B) . Table 1 shows the effect of numerous competitive agents on the uptake of b-Vn. As with the binding of b-Vn. excess unlabeled Vn (data not shown) and FBS inhibited uptake. Similarily, neither the RGD nor its inactive analog RGE peptides inhibited uptake. Moreover, a IO-fold excess of standard heparin was unable to inhibit the binding of Vn to the cell surface, but did inhibit the uptake. Conversely, a IO-fold excess of PAI-I was able to inhibit the binding of Vn to the cell surface, but had little effect on the uptake of Vn by these cells.
The uptake and intracellular targeting of b-Vn by Dami cells was visualized by immunofluorescence CLSM image analysis (Fig 7) . PMA-treated Dami cells were incubated with b-Vn for 6 hours, fixed, and not only immunostained for PAI-I (Fig 7A) , as in Fig I , but also probed with streptavidin-FITC to localize internalized b-Vn. To better visualize intracellular PAI-I and b-Vn, we performed a Z-plane crosssection through the image stacks (Fig 7A, red line) at the 5069 level of the PAI-I staining vacuole within the attenuated cytoplasm of the lower cell (white arrow) and through a PAI-l staining vacuole that overlays the nucleus of the upper transected cell. Rotation of the resulting images through 75" shows both the endogenous PAI-I (Fig 7A and C. arrows) and the exogenously added b-Vn (Fig 7B. arrow) to colocalize within the storage granules.
DISCUSSION
Active PAI-I circulates in human plasma as a binary complex with Vn.'"' Under normal conditions and durin, 0 acutephase states in humans and rats, plasma Vn levels are in 100-to 1,000-fold molar excess relative to PAI-I levels.'x~25~26 Moreover, we have shown that increases in plasma PAI-I and Vn after various acute-phase inflammatory stimuli in rats are associated with increased PAI-I and Vn mRNA expression within different hepatocellular sources that are not coordinately regulated by interleukin-6 (1L-6).'x.25.2fi In the present report, we again show divergent origins of PAI-1 and Vn found within the storage granules of PMA-treated Dami cells. We have shown that PAI-I accumulates only in cells that have been induced to differentiate by treatment with the tumor promoter PMA. whereas Vn is present in both treated and untreated cells. PAI-l is endogenously synthesized, whereas Vn is internalized from the surrounding medium.
Some molecules arise in the a-granule as a result of endogenous synthesis within the precursor megakaryocyte. Proteins known to arise in this manner include multimerin,2" vWF," platelet factor 4." and transforming growth factorKonkle et all3 have shown that PAI-I mRNA is synthesized upon activation in CHRF-288 cells. but not in HEL cells. Both of these cell lines are megakaryoblastic lines derived from human tumors. The state of maturity of the megakaryocytic phenotype and the potential for differentiation of various cell lines may affect their ability to synthesize PAI-I . Allessi et al'' used in situ hybridization to show PAI-1 mRNA in MEG-01 cells, a megakaryocytic line at an early stage of development, as well as in normal human megakaryocytes. Recent studies4" have shown that a mouse pituitary cell line capable of sorting proteins for secretion into secretory granules. when transfected with human PAI-1 cDNA constructs, can synthesize. package. and secrete PAI-I through secretory granules.The experiments presented here suggest that PAI-I also arises as a result of endogenous synthesis. PAL l mRNA expression, protein translation, sorting to storage granules, and secretion into the medium can be induced by treatment with PMA. This suggests that the synthesis and storage of PAI-I does not occur in early megakaryocyte precursors but begins as the cells differentiate down the lineage to mature megakaryocytes.
Greater than 90% of the circulating PAI-I is contained within platelets." This suggests that, in addition to perturbed endothelium,25 the bone marrow is a major site of PAI-I gene expression and that biosynthesis of PAI-I is a normal component of the hemopoietic differentiation of megakaryocytes. There is evidence that certain a-granule proteins arise from at least two sources. Megakaryocyte-associated factor For personal use only. on September 24, 2017. by guest www.bloodjournal.org From V is both endogenously synthesized and taken up from the surrounding medium.42 PAL1 accumulation in Dami cells appear to occur predominantly by endogenous synthesis. The lack of b-PAL1 binding to the Dami cell surface or its uptake by these cells suggests that there is little or no receptormediated endocytosis of PAI-l, but does not rule it out completely. Furthermore, our inability to show a significant uptake of the fluid-phase PAI-l into Dami cells supports the hypothesis that there are at least two major sources of intravascular PAI-1 within the body, the platelet-associated storage pool and de novo synthesis by endothelial cells. The proportion that each of these pools contributes to the circulating fluid-phase PAL1 is unclear. Simpson et a14' report that the plasma pool and the platelet-associated pool of PAI-l vary independently in a number of disease states. This supports the hypothesis that PAI-I circulating in the plasma may arise from the vascular endothelial or smooth muscle cells, whereas platelet-associated PAI-1 may arise from megakaryocytes, and that this pool serves a hemostatic function at sites of hemostatic plug and platelet accumulation.
Proteins can also arise in the a-granule as a result of transport from the surrounding plasma. Vn by cultured human fibroblasts has been previously shown; however, the uptake of multimeric Vn was sensitive to inhibition by RGD-containing peptides and by antibodies directed against a&, but not by those against a& . ' l' These investigators have also shown that both the native and multimeric form of Vn is bound to the cells, but only the multimeric form was internalized." Moreover, this uptake was inhibited by heparin and thrombospondin. Volker et alh2 have shown that porcine vascular endothelial cells internalize multimel-ic (denatured) Vn and that this uptake is inhibited by heparin but not by RGD peptides. Thus, our experimental findings appear to be largely consistent with these findings in cultured porcine endothelium and human fibroblasts.
There is indirect evidence from other cell sources to support the contention that Vn is synthesized in megakaryocytes and deposited in platelets before they are released into the circulation. Platelets of patients with Glanzmann thrombasthenia that lack both the GPII&II, and the a,P3 integrin receptors contain increased amounts of Vn within the agranules, whereas those that lack the GPIIJIII, but have normal or increased amounts of a& contain normal amounts of Vn." These findings cannot differentiate whether megakaryocytelplatelet Vn is synthesized endogenously and transported out of the cell via an a&-mediated process or internalized by an RGD-independent process. We are unable to show the presence of metabolically labeled Vn in the culture supernatant or cell extracts from either untreated or PMA-treated cells. RT-PCR experiments to identify Vn mRNA in untreated and PMA-treated cells were undertaken to strengthen the data obtained from the metabolic labeling experiments. This lack of an identifiable mRNA or a "Slabeled protein in our experiments strongly suggests that Vn is not synthesized by Dami cells. Thus, our data are consistent with divergent pathways of origin for Dami cell Vn and PAI-1 and that the hepatocyte is the most significant source of circulating Vn and the Vn expression in extrahepatic cell types is
The fact that Vn is known to bind and maintain PAI-1 in its active conformation brings up the question as to whether PAI-1/Vn complexes exist within the a-granule. Recent studies' indicate concommitant release of PAL1 and Vn from platelets upon thrombin stimulation, suggesting that the agranule is a common storage site. PAI-1/Vn complexes can be shown in the supernatant of activated platelet releasates. Our data indicate three-dimensional colocalization of these two molecules within Dami cells, as evidenced by the intense dual-fluorescence staining of the large storage vacuoles in the center of the cell (Fig 1) . The ultrastructural morphology of Vn-labeled filaments in Dami cells resembles the 5-to IO-nm diameter filaments associated with fibronectin-rich extracellular matrix of cultured bovine aortic endotheRotary shadow electron microscopic evaluation of purified multimeric Vn showed it to be composed of a heterogenous population of globular aggregates with an average diameter between 15 and 28 nm.23 Dual-labeled immunogold For personal use only. on September 24, 2017. by guest www.bloodjournal.org From electron microscopic examination of ultrathin sections (approximately 70 to 80 nm thickness) of bovine endothelial cell extracellular matrices65.66 and purified proteins showed PAL1 immune complexes composed of gold (4 nm) conjugated goat antimouse IgG bound to murine antibovine PAI-1 IgG, colocalized within a maximal 60 nm radius of Vn (10 nm gold) immune complexes. By comparison, our CLSM image analysis showed a high degree of three-dimensional colocalization of Vn and PAL 1 within Dami cell storage granules at a 200 nm limit of resolutuion. However, these observations do not prove whether PAI-1 and Vn exist as a complex within these storage granules. Despite colocalization within the same organelle (ie, a-granules in platelets and the storage vacuoles in Dami cells), a large proportion of platelet-associated PAL1 is believed to be inactive.67 Our preliminary evidence indicates that a significant portion of the PAI-1 secreted by activated Dami cells is active, because it inhibits t-PA-mediated plasmin generation. Detergent extracts from platelets do not release PAI-1Nn complexes.' This evidence suggests that PAL 1Nn complexes do not exist to any great extent within the a-granule but may form in the microenvironment of the platelet plug after release of the agranule contents from the activated platelet. Hep G2 cells synthesize and secrete both PAL1 and Vn, but pulse-chase studies6* indicate that they interact to form complexes only after secretion from the cell. Similarly, cultured endothelium and fibrosarcoma cells synthesize PAI-1 but not Vn, yet the secreted PAL1 forms complexes with serum-derived Vn in the culture substratum and extracellular m a t r i~.~' .~~.~~ If PAI-1 N n complexes exist in the a-granule in situ, our data would suggest that the complex does not form until the molecules are brought together from distinct sources in the a-granule. Further studies are currently ongoing to determine the role of Dami cell-associated Vn with respect to PAL1 activity.
